Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 trial of mAb114 in Africa

Trial Profile

Phase 1 trial of mAb114 in Africa

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ansuvimab (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions

Most Recent Events

  • 02 Feb 2019 New trial record
  • 24 Jan 2019 According to a National Institute of Allergy and Infectious Diseases Media Release, the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) is planning to conduct this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top